Editas Medicine (EDIT) Income towards Parent Company (2016 - 2025)
Historic Income towards Parent Company for Editas Medicine (EDIT) over the last 11 years, with Q3 2025 value amounting to -$25.1 million.
- Editas Medicine's Income towards Parent Company rose 5957.9% to -$25.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.6 million, marking a year-over-year increase of 613.13%. This contributed to the annual value of -$237.1 million for FY2024, which is 5637.63% down from last year.
- Per Editas Medicine's latest filing, its Income towards Parent Company stood at -$25.1 million for Q3 2025, which was up 5957.9% from -$51.5 million recorded in Q2 2025.
- In the past 5 years, Editas Medicine's Income towards Parent Company registered a high of -$18.9 million during Q4 2023, and its lowest value of -$75.7 million during Q1 2025.
- Its 5-year average for Income towards Parent Company is -$50.2 million, with a median of -$51.5 million in 2025.
- Per our database at Business Quant, Editas Medicine's Income towards Parent Company plummeted by 52431.9% in 2021 and then surged by 6894.66% in 2023.
- Editas Medicine's Income towards Parent Company (Quarter) stood at -$41.4 million in 2021, then tumbled by 46.58% to -$60.7 million in 2022, then surged by 68.95% to -$18.9 million in 2023, then crashed by 140.68% to -$45.4 million in 2024, then surged by 44.67% to -$25.1 million in 2025.
- Its Income towards Parent Company was -$25.1 million in Q3 2025, compared to -$51.5 million in Q2 2025 and -$75.7 million in Q1 2025.